| Long non-coding RNAs (lncRNAs) are a type of non-protein coding RNA, which have been found to play multiple
roles in various molecular and cellular processes by epigenetic regulation of gene expression at post transcriptional levels. LncRNAs may act either as an oncogene or as a tumor suppressor gene in different cancers. Aberrant
expression and dysregulation of lncRNAs has been correlated with cancer development and tumor growth via
several different signaling pathways. Therefore, lncRNAs could serve as diagnostic biomarkers and as therapeutic
targetes in many human cancers. Previous studies have reported that dysregulated expression of the lncRNA
called DLX6-AS1 in various cancer types, such as lung, colorectal, bladder, ovarian, hepatocellular, pancreatic
and gastric. DLX6-AS1 plays an important role in tumorigenesis by affecting cell proliferation, migration, invasion, EMT, and apoptosis. DLX6-AS1 exerts these regulatory effects by interfering with various microRNA axes
and signaling pathways including, Wnt/βcatenin, Notch, P13/AKT/mTOR, and STAT3. This review focuses on
the possible mechanisms by which DLX6-AS1 regulates tumor initiation and progression. Accordingly, DLX6-AS1
may act as a novel potential biomarker for cancer diagnosis or therapy in future |